Johnathan Whetstine, PhD
Research Awards Nationwide Recipient (2014-2016)
Massachusetts General Hospital, Boston, MA
Funded by the American Lung Association of the Northeast
Enzyme Could Help Predict Effectiveness of Lung Cancer Chemotherapy
Abnormal gene expression and mutations contribute to lung cancer risk and drug resistance. The enzyme KDM4A, which is over-produced in lung cancer, leads to genetic changes which have been linked to drug resistance. The overproduction of KDM4A in cancer cells results in reduced response to drug treatment and radiation. We will study how KDM4A works in lung cancer cells, and whether levels of the enzyme are an important predictor of the effectiveness of chemotherapy against lung cancer.